August 22, 2016
BioCardia, Inc. Signs Merger Agreement with Tiger X Medical, Inc., Secures Funding to Support Further Development of CardiAMP® Cell Therapy System for the Treatment of Heart Failure
May 23, 2016
BioCardia® receives award from the Maryland Stem Cell Research Fund for CardiAMP cell therapy program for the treatment of ischemic heart failure
May 9, 2016
BioCardia® Receives US Patent Covering a Method of Producing Mesenchymal Stem Cells Using a Single Patient Donor for Both Source Cells and Culture Medium
Feb 21, 2016
BioCardia®, Inc. Announces Two Presentations Related to Cardiamp Cell Therapy at Cardiovascular Research Technologies in Washington, DC
Jan 28, 2016
BioCardia Announces Upcoming Cell Therapy Presentations at Cardiovascular Research Technologies Conference
|
We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells.
These programs are enabled by the Company's Helix™ transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.
|
